Management of Leptomeningeal Metastases in Non-oncogene Addicted Non-small Cell Lung Cancer
Brain metastases in non-small cell lung cancer (NSCLC) patients are more often detected due to imaging modalities improvements but also emerge because of improved treatments of the primary tumor which lead to a longer survival. In this context, development of leptomeningeal metastases (LM) is a deva...
Main Authors: | Ana Turkaj, Anna M. Morelli, Tiziana Vavalà, Silvia Novello |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-07-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2018.00278/full |
Similar Items
-
Immunotherapy in NSCLC Patients With Brain and Leptomeningeal Metastases
by: Thomas Pierret, et al.
Published: (2022-04-01) -
A Pilot Phase 1 Study of Intrathecal Pemetrexed for Refractory Leptomeningeal Metastases From Non-small-cell Lung Cancer
by: Zhenyu Pan, et al.
Published: (2019-08-01) -
Efficacy and safety of osimertinib for leptomeningeal metastases from EGFR-mutant non-small cell lung cancer: a pooled analysis
by: Lei Wen, et al.
Published: (2023-08-01) -
Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases
by: Mei-Mei Zheng, et al.
Published: (2022-05-01) -
A case report of endometrial adenocarcinoma with leptomeningeal metastases
by: Danial Fazilat‐Panah, et al.
Published: (2021-09-01)